Rezultati pretraživanja
  1. quality of life data, as reported by participants, being presented by Lynne I. Wagner, PhD at

  2. Integrating clinical risk to the “gray zone” (age <50, RS 16-25) patients identified in helped more appropriately select chemo vs. none

  3. 20. ožu 2019.

    Tale home messages Dr Eric Winer DX

  4. 18. pro 2019.

    Oncotype makes MD Anderson List of 6 Important Advances in Breast Cancer!!!

  5. 24. tra 2019.

    New study estimates that application of OncotypeDX (a genomic test) could reduce costs for breast cancer care by about $50 million for U.S. patients in 1st year after diagnosis, - ?

  6. Patient-reported outcomes from the trial showing that significantly impact on acute symptoms; however, long-term quality of life appears the same in patients receiving endocrine therapy irrespectively of prior exposure to CT

  7. 2. lip 2019.

    Looking forward to presenting abstract 503 at on Monday at 1045AM in Hall D2 evaluating integration of clinics and genomic risk in . I suspect that you may find the potential implications of the findings surprising yet obvious.

  8. 18. lip 2019.

    Very informative updates from on the adjuvant management of early stage breast cancer.

  9. 25. stu 2019.

    Researchers find breast cancer recurrence score has different implications for men than women. New study in indicates a lower threshold is needed to predict male mortality using the genetic assay.

  10. Dr Joseph Sparano gives the William McGuire Lecture recognizing his team work on clinical risk guiding treatment

    Prikaži ovu nit
  11. 10. velj 2019.
  12. 22. velj 2019.
  13. 26. tra 2019.

    Using the approach would spare breast cancer patients from unneeded chemotherapy, thanks to ⁦⁩ Joseph Sparano, MD’s research at my former employer, ⁦⁩ . This is truly momentous!

  14. 8. ožu 2019.

    Genes drive proliferation score up but greater sensitivity to chemo which is a yen and yang effect to create the 21 gene assay for ⁩ with chair ⁦⁩ ⁦⁩ ⁦

  15. I'm trying to mirror who referred to women who enrolled on as volunteers, not subjects.

  16. 4. lip 2019.

    "The promise of “precision” medicine has collided with the rather messier world of using all available evidence to try and make educated guesses to improve patient outcomes." writes in on

  17. Presented by at and published in first results of in node-negative -positive patients with RS 26-100: are these the best candidates for -based and -free ?

  18. 7. pro 2018.

    Another day. Another poster. AAF have worse IME than CF (Higher TILs, exhausted CD8 & PDCD1/ CTLA4 expression). In time with IDFS AAF outcome. More inflamed TME? Thx Dr. Takabe for mentoring.

    Prikaži ovu nit
  19. 24. sij

    The latest with is now posted. Red Light, Pola for DLBCL, Hem/Onc Question of the Week, & with of the Fred Hutchinson Cancer Research Center

  20. 18. lip 2019.

    guidelines - caution w chemo in RS 26-31 postm: I rarely disagree w a panel I sit on but no benefit seen for chemo in older pts even at score 25 & given the data even postm + other poor prognostic markers no chemo benefit w interm RS

    Prikaži ovu nit

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.